Schizophrenia – Epidemiology – Emerging Markets

Clarivate Epidemiology’s coverage of schizophrenia comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the prevalence of schizophrenia for each country, as well as annualized case counts projected to the national population.

Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets of the United States, Europe, and Japan, and 10 years for the other countries covered in this report.

Clarivate Epidemiology’s schizophrenia forecast will answer the following questions:

  • How will improvements in survival change the number of people living with a diagnosis of schizophrenia?
  • Of all people diagnosed with schizophrenia, how many in each country across the developed world are drug-treated?
  • How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of schizophrenia over the forecast period?

All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.

Clarivate Epidemiology forecasts following schizophrenia patient populations:

  • Lifetime prevalent cases
  • Diagnosed lifetime prevalent cases
  • Diagnosed lifetime prevalent cases with depression
  • Diagnosed lifetime prevalent cases with cognitive impairment
  • Diagnosed lifetime prevalent cases with positive symptoms
  • Diagnosed drug-treated lifetime prevalent cases
  • Diagnosed lifetime prevalent cases with negative symptoms
  • Diagnosed lifetime prevalent cases with significant negative symptoms
  • Diagnosed lifetime prevalent cases with significant positive symptoms
  • … and more (details available on request).

Note: Coverage may vary by country.

launch Related Market Assessment Reports